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Abstract: To perform a systematic review assessing accuracy and
completeness of diagnostic studies of procalcitonin (PCT) for early-
onset neonatal sepsis (EONS) using the Standards for Reporting of
Diagnostic Accuracy (STARD) initiative.
EONS, diagnosed during the first 3 days of life, remains a common
and serious problem. Increased PCT is a potentially useful diagnostic
marker of EONS, but reports in the literature are contradictory. There
are several possible explanations for the divergent results including the
quality of studies reporting the clinical usefulness of PCT in ruling in or
ruling out EONS.
We systematically reviewed PubMed, Scopus, and the Cochrane
Library databases up to October 1, 2014. Studies were eligible for
inclusion in our review if they provided measures of PCT accuracy for
diagnosing EONS. A data extraction form based on the STARD check-
list and adapted for neonates with EONS was used to appraise the
quality of the reporting of included studies.
We found 18 articles (1998–2014) fulfilling our eligibility criteria
which were included in the final analysis. Overall, the results of our
analysis showed that the quality of studies reporting diagnostic accuracy
of PCT for EONS was suboptimal leaving ample room for improve-
ment. Information on key elements of design, analysis, and interpret-
ation of test accuracy were frequently missing.
Authors should be aware of the STARD criteria before starting a
study in this field. We welcome stricter adherence to this guideline.
Well-reported studies with appropriate designs will provide more
reliable information to guide decisions on the use and interpretations
of PCT test results in the management of neonates with EONS.
(Medicine 94(30):e1230)
INTRODUCTION
E arly-onset neonatal sepsis (EONS), diagnosed during thefirst 3 days of life, is a leading cause of morbidity andohn F. Osborn, Ph i, PhD,
ernhard Resch, MD
the abnormal pathophysiologic state are excluded or unlikely.3
However, even culture is not free from error because it can be
falsely sterile, as suggested by postmortem cultures,4 or because
of the low yield caused by insufficient sample volumes, inter-
mittent, or low-density bacteremia.5 Antibiotic treatment prior
to blood culture may further reduce the diagnostic performance
of blood culture.5 Yet, clinical signs may be minimal and are
similar to those of various noninfectious processes. Hence,
antibiotics are often started empirically in infants with perinatal
risk factors or clinical signs suggestive of bacterial infection.
The availability of a laboratory test to accurately and more
rapidly identify septic neonates than is done by the isolation of
microorganisms from body fluid specimens would be of con-
siderable value in improving the outcome of this challenging
clinical problem, and in minimizing unnecessary treatment of
uninfected patients during the immediate postnatal period.
Many laboratory tests including various leukocyte indices
and acute-phase proteins have been recommended for the
evaluation of suspected infection in the neonate.3 However,
the inability of any single laboratory test to provide rapid,
reliable, and early identification of infected (and, as impor-
tantly, noninfected) neonates has led to a search for other
diagnostic markers.3 Among those evaluated in recent years
has been procalcitonin (PCT).6
In 1994, Dandona et al7 showed that after the injection of
endotoxins in normal human volunteers, the PCT concentration
was undetectable at 0, 1, and 2 hours, but was detectable at
4 hours peaking at 6 hours, and maintaining a plateau through 8
and 24 hours. Because of this rapid response, the body of
literature investigating PCT in adults and children with sepsis,
as an attractive alternative to C reactive protein (CRP), has
grown rapidly over the last 2 decades,6,8,9 providing insight as
well as posing questions regarding the potential use of PCT for
the diagnosis of sepsis. However, clinicians have been less
familiar with the potential use of PCTmeasurements for clinical
purposes in neonatal patients,3 in particular those presenting
EONS.6 Increased PCT is a potentially useful diagnostic marker
of EONS, but reports in the literature are contradictory.6
In contrast to CRP, reports in the literature have shown that
PCT is an early and specific marker of neonatal sepsis, con-
firming the importance of the latter in excluding infection
shortly after birth.10 However, falsely increased PCT concen-
trations have been reported for critically ill newborns presenting
with ‘‘apparently’’ noninfectious conditions.11–16 Although
these studies argued for the lack of PCT specificity for the
diagnosis of sepsis in neonates, their conclusions should be
interpreted with caution. First, arbitrary cut-offs were used to
differentiate infectious and noninfectious clinical conditions.
For instance, in the report by Lapillonne et al,16 uninfected
neonates (mean postnatal age, 2.3 days) were deemed to haventrations on the basis of a surrogate cut-
stablished in children admitted to a
re unit. Second, interpretation on the
www.md-journal.com | 1
use of PCT was complicated by diverse study populations.10
Heterogeneity not only within the study group, but also within
categories defined as ‘‘sepsis,’’ ‘‘distress,’’ ‘‘infected,’’ ‘‘respir-
atory distress,’’ or even ‘‘hemodynamic failure,’’ has been
huge.10 Third, the PCT response was assessed in neonates with
wide-ranging differences in postnatal age (hours to weeks),10
without consideration of the gestational age and birth weight of
the baby.3 However, failure to recognize gestational- and age-
specific cut-off valuesover the first fewdaysof lifemayconfound
the interpretation of what constitutes a negative and a positive
PCT value for the diagnosis of EONS.17–21 Fourth, PCT levels
obtained from uninfected patients were not compared with PCT
reference values for each time point of evaluation. This limitation
makes it difficult to determinewhichneonatal factorsmay cause a
significant deviation. Fifth, it is uncertain how the infectious state
in the ‘‘uninfected’’ neonates was ruled out. In the report by
Monneret et al,11 high PCT concentrations were reported during
the first 4 days of life in apparently ‘‘uninfected’’ newborns who
presented with respiratory distress syndrome (RDS) of various
etiologies. However, it would be of interest to know how many
patientswith severeRDSdemonstrated clinical evidence of being
‘‘uninfected.’’ Finally, absent from these studies are data on how
the interpretation of the PCT response in the uninfected as well as
in the infected neonates might have been hampered by the
severity of the underlying illnesses (and their extent of inflam-
matory reaction).6,22 It is clear from the above that the evaluation
of the clinical usefulness of PCT in ruling in or ruling out neonatal
sepsis, in particular EONS, is dependent on study consistency. In
this article, we therefore performed a systematic review assessing
accuracy and completeness of PCT diagnostic studies for EONS
including key elements of design, conduct, and analysis accord-
ing to the Standards for Reporting of Diagnostic Accuracy
(STARD) statement.23,24
METHODS
Our systematic review was conducted, when possible, in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. Ethical
approval was not necessary for this review study.
Data Sources
We systematically reviewed PubMed, Scopus, and the
Cochrane Library databases up to October 1, 2014. The PubMed
combined search term used was: (Procalcitonin OR PCT) AND
(neonatal sepsis OR neonatal infections OR neonate). The
search terms applied to the Scopus and the Cochrane Library
were ‘‘Procalcitonin and neonate’’ and ‘‘Procalcitonin,’’
respectively. The bibliographies of relevant articles were also
hand-searched.
Study Selection Criteria
Studies were eligible for inclusion in our review if they
provided measures of PCT accuracy for diagnosing EONS,
defined by the National Institute of Child Health and Human
Development and Vermont Oxford Networks as sepsis with
onset at 3 days of age.25 We excluded studies that used a PCT
semiquantitative assay. Duplicate articles, conference abstracts,
or studies written in languages other than English were
also excluded.
Chiesa et alData Extraction
Data extraction was performed independently by 2 authors
and included the country of the research, year of publication,
2 | www.md-journal.comjournal, reference standard employed, the type of the study
design, the number and specific characteristics of the patients in
the septic and nonseptic groups (Table 1), and items related to
the quality of the methods and reporting (listed below). Specific
data regarding the PCT cut-off level used, the sensitivity,
specificity, and area under the receiver operating characteristic
(ROC) curve for the diagnosis of EONS were also extracted
(Table 1). In cases in which estimates of uncertainties around
the observed values of sensitivities and specificities were not
calculated using Wilson method,42 we calculated them.
Quality Assessment of the Included Studies
In 2003, the STARD statement was published in 13
biomedical journals.23,24,43 The STARD initiative was devel-
oped in response to accumulating evidence of poor methodo-
logical quality. Therefore, a data extraction form based on the
STARD checklist and adapted for neonates with EONS was
used to appraise the overall quality of the included studies which
is presented in Table 2. All articles were closely examined to
gauge the extent to which they adhered to the STARD checklist
by assigning a yes or no response to each item.
Twenty-five items makeup the STARD checklist. When
the papers considered in this study were assessed, only those
STARD items that have been empirically shown to have a
potentially biasing effect on the results of diagnostic accuracy
studies44–47 and those items we deemed they may account for
variation between studies in estimates of diagnostic accuracy
for neonatal sepsis were evaluated. The following features, with
corresponding STARD checklist item number, appear to have a
possible biasing effect44–47 or account for variation between
diagnostic studies on neonatal sepsis: a description of the target
population (STARD: item #3); a description of where (primary,
secondary, or tertiary care setting) patients were recruited and
where the test and the reference standard were performed
(STARD: item #3); a description of how eligible subjects were
recruited (ie, a description whether the study included: neonates
who presented only symptoms suggesting sepsis; neonates who
presented only maternal risk factors for infection; neonates in
whom diagnosis of sepsis had been already established or
excluded; a neonatal population selected from existing data
files [STARD: item #4]); a description of whether recruitment
involved either a consecutive series of patients with and without
sepsis or a subselection (STARD: item #5); a description of the
data collection process (STARD: item #6); a description of the
reference standard for diagnosis (or exclusion) of neonatal
sepsis and its rationale (ie, a description of whether: a single
or composite reference standard [reflecting 2 or more reference
standards] was used to identify all newborns positive to the test
for sepsis and verify the index test results in infected babies; a
reference standard [along with pertinent details: a single or
composite reference standard reflecting 2 or more reference
standards or noninfectious clinical conditions-STARD: item
#18] was used to exclude EONS and to verify the index test
results in uninfected babies; the reference standard was inde-
pendent of the index test [ie, whether the index test or its
comparator formed part of the reference standard in neonates
with or without sepsis—STARD: item #7]); a description of
whether categories of results of the index test (including cut-
offs) and the reference standard were defined before or after
obtaining the results (STARD: item # 9); information concern-
ing the number and training of the persons executing and
Medicine  Volume 94, Number 30, July 2015evaluating the index test and the reference standard (STARD:
item #10); a description of whether or not the readers of the
index tests and the reference standard were blind (masked) to
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 2. Quality of Reporting of PCT Accuracy Studies (1998–2014) for Diagnosing Early (72 hours)-Onset Neonatal Infection
Category and Item No. YES NO
Methods-participants
Describe the study population:
1A. the inclusion and exclusion criteria, 17 1
1B. setting, and locations where data were collected. 15 3
Describe participant recruitment:
2A. Was enrollment of patients based only on clinical signs suggesting infection? 6 12
2B. Were such patients consecutively enrolled? 4 2
2C. Was enrollment of patients based only on maternal risk factors for infection? 3 15
2D. Were such patients consecutively enrolled? 3 0
2E. Were patients identified by searching hospital records? 4 14
2F. Did the study include both patients already diagnosed with sepsis and participants in whom sepsis had been
excluded?
5 13
Describe data collection:
3. Was data collection planned before the index test and reference standard were performed (prospective study)? 9 9
Test methods
Methods pertaining to the reference standard and the index test:
4A. Was a composite reference standard used to identify all newborns with sepsis, and verify index test results in
infected babies?
17 1
4B. Was a reference standard used to exclude sepsis? 15 3
4C. Was a composite reference standard used to identify all newborns without sepsis, and verify index test results
in uninfected babies?
4 11
4D. Did the index test or its comparator form part of the reference standard? 10 8
5.Were categories of results of the index test (including cut-offs) and the reference standard defined after obtaining
the results?
16 2
6. Did the study report the number, training and expertise of the persons executing and reading the index tests and
the reference standard?
2 16
7. Was there blinding to results of the index test and the reference standard? 2 16
Statistical methods
8. Describe the statistical methods used to quantify uncertainty (i.e. 95% confidence intervals)? 1 17
9. Describe methods for calculating test reproducibility 1 17
Results-participants and test results
10A. Describe when the study was done, including beginning and ending dates of recruitment 15 3
10B. Did the study report clinical and demographic (postnatal hours or days, gestational age, birth weight, gender)
features in those with and without sepsis?
14 4
10C. Did the study report distribution of illness severity scores in those with and without sepsis? 2 16
11. Report the number of participants satisfying the criteria for inclusion that did or did not undergo the index tests
and/or or the reference standard; describe why participants failed to receive either test.
4 14
12. Report a cross-tabulation of the results (including indeterminate and missing results) by the results of the
reference standard; for continuous results report the distribution of the test results by the results of the reference
standard.
3 15
Results-estimates
13. Report measures of statistical uncertainty (i.e. 95% confidence intervals) 10 8
ere
Chiesa et al Medicine  Volume 94, Number 30, July 2015the results of the other test (STARD: item #11); a description of
the methods for calculating the precision around used measures
of diagnostic accuracy (STARD: item #12), and the reporting
of the range within which the true values were likely to lie
(STARD: item #21); a description of the methods used for
calculating test reproducibility (STARD: item #13), and the
reporting of the estimates of test reproducibility (STARD: item
#24); a description of the study population including septic and
nonseptic neonates in which tests were executed (study period,
clinical and demographic features, distribution of illness sever-
ity scores [STARD: items #14, #15, and #18]); a description of
how many participants fulfilling inclusion criteria failed to
undergo the index test or reference standard and the reasons
of failing to do so (STARD: item #16); a cross-tabulation of the
results of the index test by the results of the reference standard,
and for continuous results, a description of the distribution of
the test results by the results of the reference standard (STARD:
item #19); and a description of how indeterminate results,
missing data, and outliers of the index test were handled
14. Report how indeterminate results, missing responses and outliers of index tests w
15. Report estimates of test reproducibility(STARD: item #22).
Adequate reporting of 3 key domains, that is, descriptions
of participant recruitment, reference standard and index test,
6 | www.md-journal.comand study population, was considered essential for capturing the
global and integrative quality of reporting the accuracy of
diagnostic tests for ruling in or ruling out EONS, and therefore
they were split into various complementary items.
Two investigators (CC, BR) independently assessed the
methodological quality of all eligible studies. The interrater
agreement between these 2 reviewers was expressed as overall
agreement percentage and more formally tested with the kappa
statistic.
RESULTS
Study Selection
In Figure 1, we present the flow diagram as recommended
by the PRISMA statement showing the process of the selection
of the studies included in our review. Specifically, our search
identified a total of 273 articles (after removing the duplicates).
According to titles and abstracts, 74 of them were selected for
further assessment. After a review of full-text, 18 were eligible
handled 3 15
4 14for inclusion in our review.18,22,26–41 All articles were identified
as studies of diagnostic accuracy and stated this research
objective in the introduction. Papers were published between
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Studies  identified through database 
searching 
(n = 276) 
Additional studies identified 
through other sources 
(n =  0) 
Studies  after duplicates removed 
(n =  273) 
Studies  screened by titles 
and abstracts 
(n = 273) 
Studies excluded (n = 199) 
- Non-relevant studies  
- Non-English language 
studies 
- Experimental studies 
Full-text studies assessed 
for eligibility 
(n =  74) 
Full-text studies excluded  
(n = 56) 
- 14 Reviews      
- 7   Studies using semiquantitative  
PCT assays 
- 27 Neonatal period beyond 72 
hours of life 
- 8   Studies without reporting 
diagnostic accuracy  
Studies included in  the 
final analysis 
(n =  18) 
Studies included in 
quantitative synthesis 
(meta-analysis 
not performed) 
Medicine  Volume 94, Number 30, July 20151998 and 2014. Most studies (15/18) were performed in single
perinatal centers.
Characteristics of the Included Studies
In Table 1, we present the main characteristics of the 18
included studies. Half of the studies had a retrospective design,
while the remaining were prospective. Fourteen studies
included both preterm and term infants and the remaining 4
involved only preterm newborns. The total number of patients
included in the 18 studies was 6547, of whom 680 had EONS
and 5867 were uninfected. In all studies, the septic group
consisted of neonates with culture proven and/or clinically
diagnosed EONS. The nonseptic group consisted of ill neonates
with other conditions that were hospitalized in the neonatal unit
in all but one of these studies. There was considerable variation
in the reference standard used for diagnosing (or excluding)
EONS and thus verifying index test results.
Diagnostic Accuracy of the Included Studies
Table 1 summarizes PCT diagnostic thresholds and
accuracy measures such as PCT sensitivities and specificities
for identifying (or excluding) EONS. There was over the first
72 hours of life wide variation in PCT sampling times, PCT cut-
off values, and results in PCT diagnostic accuracy. The mini-
mum andmaximum PCT cut-off used was 0.235 and 100 ng/mL,
respectively. The observed values of sensitivity ranged from
47.4% (95% confidence interval [CI] 27.3–68.3) to 100%
(95% CI 67.6–100) and specificity from 35.3% (95% CI
17.3–58.7) to 100% (95% CI 96.8–100).
Quality of Reporting of PCT Diagnostic Studies
We evaluated the 18 included studies for compliance with
FIGURE 1. Schematic flow chart for the selection of studies.STARD guidelines. Agreement between the 2 reviewers was
very good with an overall agreement percentage of 96%. The
kappa statistic had a value of 0.93 (95% CI 0.91–0.95),
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.indicating a very good agreement. Discrepancies were rectified
by consensus.
Table 2 summarizes the extent to which the 18 studies
adhered to the STARD items. The reporting of individual items
showed wide variation. Overall, the quality of reporting of PCT
diagnostic accuracy studies on EONS over the last 2 decades
was suboptimal. Information on key elements of design,
conduct analysis, and interpretation of test accuracy were
frequently missing.
DISCUSSION
Studies of the PCT accuracy for the diagnosis of EONS
have produced discrepant results in the past. Potential sources of
the wide variation in PCT sensitivity and specificity include the
lack of consistent PCT cut-off values regardless of the time of
sampling, and differences in study sample sizes, patient demo-
graphic and clinical characteristics, and participant recruitment.
We therefore evaluated the quality of reporting of PCT
accuracy studies for diagnosing EONS. The importance of
describing how eligible subjects were identified cannot be
overemphasized. Selection of a study population is critical in
appraising a diagnostic test.48 It is crucial to describe the
population from which patients and patient controls originated,
as it allows an assessment of the population ‘‘spectrum of
disease.’’ Reported estimates of diagnostic accuracy may have
limited clinical applicability in external populations (general-
izability) if the spectrum of tested patients is not similar to the
patients for whom the test will be used in practice.49,50 Our
analysis showed that while some PCT accuracy studies enrolled
only neonates who were suspected of having the disease
because of presenting symptoms, other studies recruited neo-
nates who were (initially asymptomatic and) only at risk of
developing the disease because of history of maternal risk
factors. Yet, other studies included neonates already diagnosed
with sepsis and participants in whom sepsis had been already
excluded. Finally, there were also designs starting with: 2
separate selection processes to sample patients with sepsis
and patients without sepsis (a sampling method producing
biased estimates of accuracy known as ‘‘the diagnostic case–
control’’ with limited spectrum);44,51 nonconsecutive sampling
of patients (a sampling method leading to the ‘‘limited chal-
lenge bias’’);52 retrospective data collection; and identification
of patients by searching hospital records. These alternative
study designs are likely to influence the spectrum of disease
in the included patients, and estimates of diagnostic accuracy. In
a study of evidence of bias and variation in diagnostic accuracy
studies, Rutjes et al46 found that the largest overestimation of
accuracy was found in studies that included severe cases and
healthy controls and in those in which 2 or more reference
standards were used to verify index test results. The design
features associated with overestimation of diagnostic accuracy
were also nonconsecutive inclusion of patients, and retrospec-
tive data collection.46 In contrast, the selection of patients on the
basis of whether they had been referred for the index test or on
the basis of previous test results, rather than on clinical symp-
toms, was significantly associated with lower estimates of
accuracy.46
The spectrum of sepsis as well as the range of other
conditions that occur in patients suspected of sepsis can vary
from setting to setting, depending on what referral mechanisms
Procalcitonin in the Early Neonatal Periodwere in play.53–55 Thus, the accuracy of tests may vary between
primary care and secondary or tertiary care.24 Most PCT
accuracy studies on EONS reported this issue properly by
www.md-journal.com | 7
endorsed to improve the awareness of design features, thespecifying that the neonatal intensive care setting was the
healthcare setting where data were collected.
Spectrum bias also results from differences in the severity
of sepsis/EONS between populations. It may be that some of the
variation in PCT sensitivity in the diagnosis of EONS among
published reports might have reflected differences in baseline
severity and risk status. Although individual clinical and demo-
graphic attributes of the septic and nonseptic neonatal popu-
lations were reported in most PCT diagnostic accuracy studies
(14/18), proxy measures of morbidity such as gestational age
and birth weight do not capture the overall morbidity status.
Therefore, it is of greater concern that reporting of the distri-
bution of scores of major measures of illness severity was poor
in neonates with and without sepsis.
Differential verification bias is also a key issue in any
diagnostic accuracy study. It occurs when some of the index test
results are verified by one type of reference standard and other
results by a different standard.49 The effect of differential
verification depends on the quality of the different reference
tests used. Differential verification poses a problem if the
reference standards differ in accuracy and if the choice of
reference standard relates to the results of the index test.49 This
usually occurs when patients testing positive on the index test
receive a more accurate reference standard than those testing
negative. Previous studies that relied on 2 or more reference
standards to verify the results of the index test reported esti-
mates of diagnostic accuracy on average 60% higher than those
encountered in studies that used a single reference standard.46
The origin of this difference probably resides in differences
between the reference standards in how they define sepsis, or in
their quality.50 Reference standards are not interchangeable.
They may not have the same degree of error and may not
identify the same segment of the disease spectrum. Thus,
worrisome is the fact that in most of the included PCT diag-
nostic accuracy studies different reference standards were used
to diagnose (or exclude) EONS and verify index test results.
A further step in the critical appraisal of PCT accuracy
studies on EONS is whether the reference standard was inde-
pendent of the index test and the comparator of the index
test.48,56,57 When the result of the index test or its comparator
is used in establishing the reference standard, incorporation bias
may occur. Unfortunately, in 10 (55.5%) of the 18 included
studies, the comparator of the index test such as CRP test was
also a component of the reference standard. In such situations, it
is likely that the person interpreting the results of the compara-
tor will have knowledge of the results of the other test (index test
and reference standard).50
In order to make a valid comparison between the index test
and the standard test, it is essential that the criteria (cut-off
values, etc.) are defined before the start of the study. If the cut-
offs are decided after the results are obtained, the likelihood that
another study will replicate the findings is reduced. Apparently
most studies (16/18) included cut-offs post hoc.
We also determined whether the interpretation of the index
test or reference standard was influenced by knowledge of the
results of the other test. Interpretation of the results of the index
test may be influenced by knowledge of the results of the
reference standard, and vice versa.48,50 This may lead to inflated
measures of diagnostic accuracy. Information about masking
was reported in only 2 of the 18 evaluated reports.
Methods for calculating PCT test reproducibility and
Chiesa et almeasures of test reproducibility were reported poorly, by only
1 and 4 of the 18 included articles, respectively. There may
be a lack of understanding about the implications of poor
8 | www.md-journal.comreproducibility on the overall utility of a test. Furthermore,
the value of sensitivity and specificity estimates are unclear in
the absence of precise information about test reproducibility.
Information regarding the number, training, and expertise
of the persons involved in the execution, and reading of the
index test and the reference standard was also among the least
commonly reported items of the STARD guidelines. There may
be a lack of understanding of the effects of the low level of
expertise on the final outcome of the diagnostic accuracy of a
test. On the other hand, knowledge of the numbers, training, and
experience of operators would help to estimate the repeatability
of the test results in different settings.
Measures of diagnostic accuracy will be biased if the result
of the index test influences the decision to order the reference
standard (an effect known as ‘‘partial verification bias’’).48,58–64
According to the STARD statement,24 partial verification bias
occurs in up to 26% of diagnostic studies.61 It is therefore
important to describe howmany participants satisfying inclusion
criteria failed to undergo index or reference tests and the reasons
of failing to do so. This item was reported in a minority of the
included publications (4/18). A flow diagram is highly recom-
mended to illustrate the design of the study and provide the exact
number of participants at each stage of the study;23,24 only 2 of the
18 PCT diagnostic accuracy studies had a flow diagram.
Since the reported values of sensitivity, specificity, and
area under the ROC curve are only estimates, measures of
uncertainty (such as CIs) give readers a range within which true
values may lie and indicate the precision of the diagnostic test.65
CIs were reported in more than half (11/18) of the included
studies. However, only one of the 18 studies adequately
reported and cited the statistical methods used to quantify these
estimates of diagnostic accuracy.
Diagnostic tests may report uninterpretable results for
some patients, or call results uncertain, indeterminate, or inter-
mediate. The frequency of such results can vary widely between
tests.57 These problems are sometimes not reported in diag-
nostic accuracy studies or ignored in analyses.66 The frequency
of these results, by itself, is an important clue of the overall
utility of a test.67,68 This item was reported in only 3 of the
18 studies.
Since the technology for existing tests is rapidly improv-
ing, it is important to report the actual dates when the study was
performed. This will allow the reader to consider any techno-
logic advances since the study was done. Fortunately, this
information was provided in most publications.
In general, the results of our analysis of PCT diagnostic
accuracy studies for EONS provide further evidence of the
importance of design features in studies of diagnostic accuracy.
Studies of the same test can produce different estimates of
diagnostic accuracy depending on choices in design. We feel
that our results should be taken into account by researchers
when designing new PCT accuracy studies for diagnosis of
EONS as well as by reviewers and readers who appraise these
studies. In that vein, initiatives such as STARD should be
Medicine  Volume 94, Number 30, July 2015quality of reporting and, ultimately, the quality of study designs
before starting a PCT study.
CONCLUSIONS
With respect to the clinical usefulness of PCT in diagnos-ing or ruling out EONS, it is time to debate the methods used to
measure PCT performance, rather than just how a given test
performs. To interpret correctly the results of PCT accuracy
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
studies for EONS, readers must understand the design, conduct,
and data analysis and must be able to judge the internal validity
and generalizability of the results. This goal can only be
achieved through complete transparency of the reporting of
the articles. The results of our analysis involving PCT accuracy
in diagnosing EONS show that the quality of reporting for many
of the STARD items, that have been shown to have a potentially
biasing effect on the results of diagnostic accuracy studies or
appear to account for variation between studies, is substandard.
For this reason, this article does not include any summary
results or meta-analysis. Authors and peer reviewers are encour-
aged to adhere to and enforce the STARD guidelines, because
there is clearly room for improvement in the reporting of PCT
diagnostic accuracy studies for EONS.
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